Drug intelligence / Profile preview

BD-300

Development stage: Preclinical
Lead developer: Biolojic Design
Modality: Antibody-Based Therapeutics

Overview

BD-300 is an investigational antibody drug developed by Biolojic Design. It functions as a Treg (regulatory T cell) modulator, aiming to influence immune system activity by targeting regulatory T cells. The primary therapeutic area for BD-300 is immune system diseases, with a specific focus on autoimmune diseases. As of the latest update, BD-300 remains in preclinical development and has not yet entered clinical trials or received regulatory approval[1].

Beyond the preview

Go deeper on BD-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BD-300.

Explore the full profile